Including Specific Measures for Advancing ESG Management
[Asia Economy Reporter Lee Gwanju] SK Biopharm announced on the 13th that it has published the "2022 SK Biopharm Sustainability Management Report," which contains the achievements and plans for advancing ESG (Environmental, Social, and Governance) management.
This report is the second publication following last year. It includes the implementation status of the "Five Key Areas of Focus in Sustainability Management" and the core goals and action plans to be achieved in the future.
Through the global supply of the epilepsy treatment Cenobamate and social responsibility activities, SK Biopharm created approximately KRW 152.1 billion in social value (SV) last year in the healthcare value area, including economic indirect contribution performance, business social performance, and social contribution social performance. Next year, under the strategy to maximize social value through technological capabilities and business competitiveness and to lead the global central nervous system field, the company set goals to enhance social value through new drugs and to more than double the number of countries where products are launched compared to 2020.
In the "Minimizing Environmental Impact" area, SK Biopharm revealed that 54% of its electricity consumption last year was supplied by renewable energy through K-RE100, and it specified the mid- to long-term plan of "Net Zero by 2040" announced the previous year. To reduce carbon emissions by 33% by 2030 and 66% by 2035, the company plans to establish an emissions inventory by 2025, promote greenhouse gas reduction management across the entire supply chain, and begin direct emission reduction activities starting in 2026.
In the "Sustainable Partnership" area, the goal is to obtain 100% cooperation partner signatures on the ESG guidelines established and distributed last year and to achieve 100% ESG risk assessment coverage of major partners. In the "Capable and Happy Members" area, SK Biopharm plans to establish and implement its unique talent development system, and in the "Transparent and Ethical Management" area, it intends to focus on minimizing anti-corruption and compliance risks and increasing stakeholder trust.
Jungwoo Cho, CEO of SK Biopharm, said, "Despite the difficult conditions due to COVID-19, we have completed entry into the global top four markets including the U.S., Europe, Japan, and China, leading the realization of social and economic value. Going forward, we will strive to improve the social and environmental conditions of the global pharmaceutical bio industry and community and expand ESG management to continuously supply high-quality and safe pharmaceuticals to the global market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
